301 related articles for article (PubMed ID: 25978432)
1. Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma.
Hideshima T; Cottini F; Ohguchi H; Jakubikova J; Gorgun G; Mimura N; Tai YT; Munshi NC; Richardson PG; Anderson KC
Blood Cancer J; 2015 May; 5(5):e312. PubMed ID: 25978432
[TBL] [Abstract][Full Text] [Related]
2. HDAC6‑selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in multiple myeloma.
Won HR; Lee DH; Yeon SK; Ryu HW; Kim GW; Kwon SH
Int J Oncol; 2019 Aug; 55(2):499-512. PubMed ID: 31268156
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor.
North BJ; Almeciga-Pinto I; Tamang D; Yang M; Jones SS; Quayle SN
PLoS One; 2017; 12(3):e0173507. PubMed ID: 28264055
[TBL] [Abstract][Full Text] [Related]
4. Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma.
Hirano M; Imai Y; Kaito Y; Murayama T; Sato K; Ishida T; Yamamoto J; Ito T; Futami M; Ri M; Yasui H; Denda T; Tanaka Y; Ota Y; Nojima M; Kamikubo Y; Gotoh N; Iida S; Handa H; Tojo A
J Exp Clin Cancer Res; 2021 Mar; 40(1):110. PubMed ID: 33757580
[TBL] [Abstract][Full Text] [Related]
5. A452, HDAC6-selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in IMiDs-resistant multiple myeloma.
Kim GW; Yoo J; Won HR; Yeon SK; Lee SW; Lee DH; Jeon YH; Kwon SH
Leuk Res; 2020 Aug; 95():106398. PubMed ID: 32512378
[TBL] [Abstract][Full Text] [Related]
6. Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide.
Das DS; Ray A; Song Y; Richardson P; Trikha M; Chauhan D; Anderson KC
Br J Haematol; 2015 Dec; 171(5):798-812. PubMed ID: 26456076
[TBL] [Abstract][Full Text] [Related]
7. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
Bjorklund CC; Lu L; Kang J; Hagner PR; Havens CG; Amatangelo M; Wang M; Ren Y; Couto S; Breider M; Ning Y; Gandhi AK; Daniel TO; Chopra R; Klippel A; Thakurta AG
Blood Cancer J; 2015 Oct; 5(10):e354. PubMed ID: 26430725
[TBL] [Abstract][Full Text] [Related]
8. Crucial role of HO-1/IRF4-dependent apoptosis induced by panobinostat and lenalidomide in multiple myeloma.
Tang S; Ma D; Cheng B; Fang Q; Kuang X; Yu K; Wang W; Hu B; Wang J
Exp Cell Res; 2018 Feb; 363(2):196-207. PubMed ID: 29317217
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitor BG45-mediated HO-1 expression induces apoptosis of multiple myeloma cells by the JAK2/STAT3 pathway.
Tang S; Cheng B; Zhe N; Ma D; Xu J; Li X; Guo Y; Wu W; Wang J
Anticancer Drugs; 2018 Jan; 29(1):61-74. PubMed ID: 29049036
[TBL] [Abstract][Full Text] [Related]
10. [Discovery of the target for immunomodulatory drugs (IMiDs)].
Ito T; Ando H; Handa H
Rinsho Ketsueki; 2016 May; 57(5):556-62. PubMed ID: 27263779
[TBL] [Abstract][Full Text] [Related]
11. MUC1-C is a target in lenalidomide resistant multiple myeloma.
Yin L; Tagde A; Gali R; Tai YT; Hideshima T; Anderson K; Avigan D; Kufe D
Br J Haematol; 2017 Sep; 178(6):914-926. PubMed ID: 28643330
[TBL] [Abstract][Full Text] [Related]
12. The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NFκB signalling pathway.
Smith EM; Zhang L; Walker BA; Davenport EL; Aronson LI; Krige D; Hooftman L; Drummond AH; Morgan GJ; Davies FE
Oncotarget; 2015 Jul; 6(19):17314-27. PubMed ID: 26015393
[TBL] [Abstract][Full Text] [Related]
13. Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma.
Cheriyath V; Kuhns MA; Kalaycio ME; Borden EC
Br J Cancer; 2011 Mar; 104(6):957-67. PubMed ID: 21364585
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulatory drugs in the treatment of multiple myeloma.
Abe Y; Ishida T
Jpn J Clin Oncol; 2019 Aug; 49(8):695-702. PubMed ID: 31187860
[TBL] [Abstract][Full Text] [Related]
15. HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide.
Canella A; Cordero Nieves H; Sborov DW; Cascione L; Radomska HS; Smith E; Stiff A; Consiglio J; Caserta E; Rizzotto L; Zanesi N; Stefano V; Kaur B; Mo X; Byrd JC; Efebera YA; Hofmeister CC; Pichiorri F
Oncotarget; 2015 Oct; 6(31):31134-50. PubMed ID: 26429859
[TBL] [Abstract][Full Text] [Related]
16. The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo.
Sanchez E; Shen J; Steinberg J; Li M; Wang C; Bonavida B; Chen H; Li ZW; Berenson JR
Leuk Res; 2011 Mar; 35(3):373-9. PubMed ID: 20650529
[TBL] [Abstract][Full Text] [Related]
17. [Immunomodulatory drugs (IMiDs)].
Oshima K; Ichinohe T
Nihon Rinsho; 2014 Jun; 72(6):1130-5. PubMed ID: 25016816
[TBL] [Abstract][Full Text] [Related]
18. RhoB upregulation leads to either apoptosis or cytostasis through differential target selection.
Marlow LA; Bok I; Smallridge RC; Copland JA
Endocr Relat Cancer; 2015 Oct; 22(5):777-92. PubMed ID: 26206775
[TBL] [Abstract][Full Text] [Related]
19. The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomide.
Schmitt S; Ho AD; Goldschmidt H
Onkologie; 2010; 33(4):183-6. PubMed ID: 20389145
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapy.
Kaufman JL; Fabre C; Lonial S; Richardson PG
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):370-6. PubMed ID: 23787122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]